Adaptive Biotechnologies (ADPT) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $4.71B
- As of Nov 13, 2026
- P/E
- -67.23x
- Trailing twelve months
- P/B
- 26.74x
- Latest reported equity
- P/S
- 15.74x
- Trailing twelve months
- ROE
- -39.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $4.71B
- As of Nov 13, 2026
- P/E
- -67.23x
- Trailing twelve months
- P/B
- 26.74x
- Latest reported equity
- P/S
- 15.74x
- Trailing twelve months
- ROE
- -39.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-67.23x
Net loss — not comparable
P/B
26.74x
P/S
15.74x
Earnings and dividend metrics▾
Earnings
EPS
-$0.43
Earnings per share
BPS
$1.09
Book value per share
ROE
-39.8%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.43 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $1.09 of net assets.
- ROE — shareholder equity shrank by 39.8% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue decreased 10.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $94M-10.6%
$46M
Jul–Sep '24
$94M
Jul–Sep '25
$84M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share decreased 66.7% from the same quarter a year earlier.
- Revenue decreased 10.6% from the same quarter a year earlier.
- Net income decreased 70.0% from the same quarter a year earlier.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- RUBINSTEIN JULIEPresident and COO · Nov 13, 2026Open-market sale11,466 shares · $332KAvg. price $28.93377,802 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 13, 2026Option exercise11,466 shares · $139KAvg. price $12.14389,268 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 12, 2026Open-market sale11,881 shares · $349KAvg. price $29.4377,802 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 12, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 11, 2026Open-market sale11,881 shares · $366KAvg. price $30.8299
Show 2 price lots
- 6,898 shares × $31.22$215K
- 4,983 shares × $30.29$151K
- BOBULSKY SUSANChief Commercial Officer, MRD · Nov 11, 2026Open-market sale1,875 shares · $60KAvg. price $32387,475 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 11, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 10, 2026Open-market sale11,881 shares · $351KAvg. price $29.5195
Show 2 price lots
- 9,981 shares × $29.35$293K
- 1,900 shares × $30.41$58K
- RUBINSTEIN JULIEPresident and COO · Nov 10, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 9, 2026Open-market sale11,881 shares · $358KAvg. price $30.1184
Show 3 price lots
- 8,381 shares × $30.15$253K
- 2,400 shares × $30.58$73K
- 1,100 shares × $28.87$32K
- RUBINSTEIN JULIEPresident and COO · Nov 9, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- ROBINS CHAD MCEO and Chairman · Nov 9, 2026Gift100,000 shares · $0Avg. price $02,080,518 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 6, 2026Open-market sale11,881 shares · $327KAvg. price $27.4841
Show 2 price lots
- 8,400 shares × $27.32$229K
- 3,481 shares × $27.88$97K
- RUBINSTEIN JULIEPresident and COO · Nov 6, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 5, 2026Open-market sale11,881 shares · $315KAvg. price $26.5255
Show 3 price lots
- 5,926 shares × $26.1$155K
- 5,455 shares × $26.88$147K
- 500 shares × $27.7$14K
- RUBINSTEIN JULIEPresident and COO · Nov 5, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 4, 2026Open-market sale11,881 shares · $313KAvg. price $26.3239
Show 2 price lots
- 7,881 shares × $26.6$210K
- 4,000 shares × $25.78$103K
- RUBINSTEIN JULIEPresident and COO · Nov 4, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 3, 2026Open-market sale11,881 shares · $309KAvg. price $25.98377,802 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 3, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Nov 2, 2026Open-market sale11,881 shares · $303KAvg. price $25.4715
Show 2 price lots
- 9,296 shares × $25.23$235K
- 2,585 shares × $26.34$68K
- RUBINSTEIN JULIEPresident and COO · Nov 2, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Oct 30, 2026Open-market sale11,881 shares · $318KAvg. price $26.7314
Show 2 price lots
- 9,486 shares × $26.55$252K
- 2,395 shares × $27.45$66K
- RUBINSTEIN JULIEPresident and COO · Oct 30, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Oct 29, 2026Open-market sale11,881 shares · $336KAvg. price $28.27377,802 shares held after
- RUBINSTEIN JULIEPresident and COO · Oct 29, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Oct 28, 2026Open-market sale11,881 shares · $338KAvg. price $28.4477
Show 2 price lots
- 11,681 shares × $28.44$332K
- 200 shares × $28.9$6K
- RUBINSTEIN JULIEPresident and COO · Oct 28, 2026Option exercise11,881 shares · $144KAvg. price $12.14389,683 shares held after
- RUBINSTEIN JULIEPresident and COO · Oct 27, 2026Open-market sale8,881 shares · $244KAvg. price $27.53377,802 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Adaptive Biotechnologies (ADPT) stock information
NASDAQ
Adaptive Biotechnologies (ADPT) is listed on NASDAQ. Its market capitalization is about $4.7B. On trailing-twelve-month earnings the P/E ratio is -67.23, and the P/B ratio is 26.74. Return on equity is -39.8%. These figures are computed in-house from official filings and are reference information only.
Adaptive Biotechnologies — frequently asked questions
- What is the P/E ratio of Adaptive Biotechnologies (ADPT)?
- On a trailing-twelve-month basis, ADPT trades at a P/E ratio of -67.23. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Adaptive Biotechnologies?
- ADPT has a market capitalization of about $4.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.